Free Trial

Chemed Corporation (NYSE:CHE) Short Interest Up 23.2% in May

Chemed logo with Medical background

Chemed Corporation (NYSE:CHE - Get Free Report) was the target of a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 422,900 shares, an increase of 23.2% from the May 15th total of 343,400 shares. Approximately 2.9% of the shares of the company are short sold. Based on an average daily trading volume, of 130,100 shares, the short-interest ratio is presently 3.3 days.

Insider Buying and Selling

In related news, CEO Kevin J. Mcnamara sold 1,500 shares of Chemed stock in a transaction on Monday, May 5th. The shares were sold at an average price of $576.45, for a total value of $864,675.00. Following the transaction, the chief executive officer now owns 101,197 shares in the company, valued at $58,335,010.65. This trade represents a 1.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 5,500 shares of company stock valued at $3,213,780. Company insiders own 3.29% of the company's stock.

Institutional Trading of Chemed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Atala Financial Inc acquired a new stake in Chemed during the fourth quarter valued at approximately $29,000. Alpine Bank Wealth Management acquired a new position in shares of Chemed in the 1st quarter worth approximately $29,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Chemed by 64.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 56 shares of the company's stock worth $30,000 after buying an additional 22 shares during the period. HM Payson & Co. acquired a new stake in Chemed in the 1st quarter valued at $30,000. Finally, SVB Wealth LLC bought a new stake in Chemed in the first quarter valued at $30,000. Institutional investors own 95.85% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CHE. Wall Street Zen raised Chemed from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Royal Bank Of Canada upped their price target on Chemed from $667.00 to $674.00 and gave the stock an "outperform" rating in a report on Monday, April 28th.

Get Our Latest Analysis on CHE

Chemed Stock Performance

Shares of CHE traded down $3.65 during trading hours on Thursday, reaching $546.00. 120,431 shares of the company traded hands, compared to its average volume of 104,676. The stock's fifty day moving average is $569.45 and its 200 day moving average is $565.09. Chemed has a 1-year low of $512.12 and a 1-year high of $623.61. The stock has a market cap of $7.99 billion, a P/E ratio of 26.60, a price-to-earnings-growth ratio of 2.28 and a beta of 0.54.

Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $5.63 EPS for the quarter, beating the consensus estimate of $5.59 by $0.04. Chemed had a return on equity of 27.58% and a net margin of 12.40%. The firm had revenue of $646.94 million during the quarter, compared to analysts' expectations of $641.78 million. During the same quarter in the prior year, the firm posted $5.20 EPS. The company's revenue for the quarter was up 9.8% on a year-over-year basis. On average, equities research analysts predict that Chemed will post 21.43 EPS for the current year.

Chemed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 17th. Stockholders of record on Thursday, May 29th were given a dividend of $0.50 per share. The ex-dividend date was Thursday, May 29th. This represents a $2.00 annualized dividend and a dividend yield of 0.37%. Chemed's dividend payout ratio (DPR) is currently 9.74%.

Chemed Company Profile

(Get Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Chemed Right Now?

Before you consider Chemed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.

While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Drone Industry Is About to 10X—Here’s How to Profit
Why AMD Stock Beats NVIDIA Right Now
Oil Spikes Amid Rising Warfare: 3 Stocks to Watch Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines